Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · IEX Real-Time Price · USD
112.19
-1.50 (-1.32%)
Jul 26, 2024, 4:30 PM EDT - Market closed

Blueprint Medicines Revenue

Blueprint Medicines had revenue of $96.12M in the quarter ending March 31, 2024, with 51.87% growth. This brings the company's revenue in the last twelve months to $282.21M, up 37.94% year-over-year. In the year 2023, Blueprint Medicines had annual revenue of $249.38M with 22.22% growth.

Revenue (ttm)
$282.21M
Revenue Growth
+37.94%
P/S Ratio
25.22
Revenue / Employee
$430,853
Employees
655
Market Cap
7.02B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023249.38M45.34M22.22%
Dec 31, 2022204.04M23.96M13.30%
Dec 31, 2021180.08M-613.66M-77.31%
Dec 31, 2020793.74M727.22M1,093.37%
Dec 31, 201966.51M21.99M49.39%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Jazz Pharmaceuticals 3.84B
Penumbra 1.10B
HealthEquity 1.04B
Halozyme Therapeutics 862.99M
Ionis Pharmaceuticals 776.62M
Repligen 607.45M
Ascendis Pharma 357.63M
Revolution Medicines 4.57M
Revenue Rankings